We are live on ! Find out more
EC

Euclidean Capital Portfolio holdings

AUM $392M
1-Year Est. Return 31.85%
This Fund
S&P 500
This Quarter Est. Return
+7.05%
1 Year Est. Return
+31.85%
3 Year Est. Return
+76.27%
5 Year Est. Return
-20.16%
10 Year Est. Return
–
AUM
$389M
AUM Growth
+$275M
Cap. Flow
+$262M
Cap. Flow %
67.34%
Top 10 Hldgs %
99.39%
Holding
12
New
2
Increased
4
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$103M
2
GLD icon
SPDR Gold Trust
GLD
+$102M
3
INDA icon
iShares MSCI India ETF
INDA
+$50.7M
4
RAPT
RAPT Therapeutics
RAPT
+$2.69M
5
FHTX icon
Foghorn Therapeutics
FHTX
+$2.19M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 19.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
State Street SPDR S&P 500 ETF Trust
SPY
$795B
$109M 28.05%
+246,250
New +$103M
INDA icon
2
iShares MSCI India ETF
INDA
$6.89B
$106M 27.23%
2,425,144
+1,225,000
+102% +$50.7M
GLD icon
3
SPDR Gold Trust
GLD
$131B
$98.9M 25.43%
+555,000
New +$102M
ME
4
DELISTED
23andMe Holding Co
ME
$17.9M 4.61%
512,156
– –
PMVP icon
5
PMV Pharmaceuticals
PMVP
$59.2M
$15.9M 4.09%
2,545,242
+208,333
+9% +$1.09M
FHTX icon
6
Foghorn Therapeutics
FHTX
$266M
$11.1M 2.85%
1,573,761
+312,500
+25% +$2.19M
RAPT
7
DELISTED
RAPT Therapeutics
RAPT
$10.7M 2.75%
71,404
+17,291
+32% +$2.69M
ALEC icon
8
Alector
ALEC
$168M
$5.9M 1.51%
980,894
– –
ORIC icon
9
Oric Pharmaceuticals
ORIC
$1.15B
$5.8M 1.49%
747,550
– –
TNYA icon
10
Tenaya Therapeutics
TNYA
$161M
$5.38M 1.38%
915,705
– –
NGM
11
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.93M 0.5%
746,674
– –
SRZN icon
12
Surrozen
SRZN
$258M
$442K 0.11%
53,531
– –

Similar funds

WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
RC
Riposte Capital New York $392M AUM 69.08% 1-Year Est. Return
DCM
Divisar Capital Management San Francisco, California $392M AUM 108.45% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
BWM
Buckley Wealth Management Las Vegas, Nevada $392M AUM 28.21% 1-Year Est. Return
IPW
Inlet Private Wealth Jupiter, Florida $392M AUM 25.74% 1-Year Est. Return
TCM
Turas Capital Management Boston, Massachusetts $392M AUM
MA
Mezzasalma Advisors Tinton Falls, New Jersey $391M AUM 40.85% 1-Year Est. Return

Euclidean Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Euclidean Capital held 12 positions worth $389M, up 241% from $114M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Euclidean Capital deployed $262M of net new capital in Q2 2023, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 246,250 shares worth $109M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 59% a quarter earlier.

  • Euclidean Capital's largest Q2 2023 buy was State Street SPDR S&P 500 ETF Trust: 246,250 shares worth $109M.
  • Euclidean Capital added most to iShares MSCI India ETF in Q2 2023, an estimated $50.7M increase.
  • Euclidean Capital's ten largest holdings make up 99% of its $389M portfolio in Q2 2023.
  • Euclidean Capital opened 2 new positions and closed 0 in Q2 2023.
  • Euclidean Capital's portfolio value rose 241% quarter-over-quarter to $389M.

Based on Euclidean Capital's 13F filing for Q2 2023, filed 14 Aug 2023.